EP0127535A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Pharmaceutical compositions containing insulin
Assignee: Hadassah Medical Organization
•
Filing: 1984-05-21
•
Granted: —
•
Expires: 2004-05-21
Abstract
Abstract The invention provides a pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof, the bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3β-hydroxy-12- ketocholic acid, 12α-3β-dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, the composition being provided with an enterocoating to assure passage through the stomach and release in the intestine.
Inventors
- 👤 Miriam Kidron
- 👤 Ehud Ziv
- 👤 Hanoch Bar-On
- 👤 Amiram Eldor
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-26 18:32
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/28; A61K38/55; A61K9/00; A61K9/20; A61K9/2004; A61K9/2013; A61K9/2068; A61K9/28; A61K9/2806; A61K9/2833; A61K9/284; A61K9/2846
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
75 words
A pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof, said bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid,taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3β-monohydroxychloric acid, lithocholic acid, 3a-hydroxy-12-ketocholic acid, 3β-hydroxy-12-ketocholic acid, 12a-3a-dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, said composition being provided with an enterocoating to assure passage through the stomach and release in the intestine.
Claim 2
Dependent Claim
75 words
A pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof, said bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid,taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3β-monohydroxychloric acid, lithocholic acid, 3a-hydroxy-12-ketocholic acid, 3β-hydroxy-12-ketocholic acid, 12a-3a-dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, said composition being provided with an enterocoating to assure passage through the stomach and release in the intestine.
Claim 3
Dependent Claim
34 words
A pharmaceutical composition according to claim 1, wherein said protease inhibitor is selected from the group consisting of aprotinin, A 2 -macroglobulin, antithrombin III and trypsin inhibitor from soy bean or chicken egg white.
Claim 4
Dependent Claim
19 words
A pharmaceutical composition according to claim 1, comprising sodium cholate as both the bile acid and the protease inhibitor.
Claim 5
Dependent Claim
26 words
A pharmaceutical composition according to claim 1,wherein the components of said composition are microencapsulated and enterocoated to provide for timed release of ingredients in the intestine.
Claim 6
Dependent Claim
3 words
CLAIMS (for AT)
Claim 7
Dependent Claim
90 words
A process for preparing a pharmaceutical composition for the oral administration of insulin, characterized in that it comprises mixing active ingredients consisting of insulin, a bile acid or alkali metal salt thereof, said bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 36-monohydroxychloric acid, lithocholic acid, 30(-hydroxy-12-ketocholic acid, 3β-hydroxy-12-ketocholic acid, 12α-3β-dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, and providing said active components with an enterocoating to assure passage through the stomach and release in the intestine.
Claim 8
Dependent Claim
90 words
A process for preparing a pharmaceutical composition for the oral administration of insulin, characterized in that it comprises mixing active ingredients consisting of insulin, a bile acid or alkali metal salt thereof, said bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 36-monohydroxychloric acid, lithocholic acid, 30(-hydroxy-12-ketocholic acid, 3β-hydroxy-12-ketocholic acid, 12α-3β-dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, and providing said active components with an enterocoating to assure passage through the stomach and release in the intestine.
Claim 9
Dependent Claim
53 words
Process according to claim 1, characterized in that said active components are mixed with a solid vehicle, the mixture thus obtained is mechanically pressed to form tablets, the later are coated with a solution of an enterocoating polymer in an organic solvent and the organic solvent is then removed from the coated tablets.
Claim 10
Dependent Claim
23 words
Process according to claim 2, characterized in that the solid vehicle is lactose and the organic solvent is a methylene chloride-isopropyl alcohol mixture.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.